炎症体
促炎细胞因子
结肠炎
组织蛋白酶B
半胱氨酸蛋白酶1
组织蛋白酶
炎症性肠病
化学
炎症
免疫学
分泌物
组织蛋白酶L
医学
生物化学
内科学
酶
疾病
作者
Christian Bauer,Peter Duewell,Christine Mayer,Hans A. Lehr,Katherine A. Fitzgerald,M Dauer,J Tschopp,Stefan Endres,Eicke Latz,Max Schnurr
出处
期刊:Gut
[BMJ]
日期:2010-05-04
卷期号:59 (9): 1192-1199
被引量:863
标识
DOI:10.1136/gut.2009.197822
摘要
BACKGROUND: The proinflammatory cytokines interleukin 1beta (IL-1beta) and IL-18 are central players in the pathogenesis of inflammatory bowel disease (IBD). In response to a variety of microbial components and crystalline substances, both cytokines are processed via the caspase-1-activating multiprotein complex, the NLRP3 inflammasome. Here, the role of the NLRP3 inflammasome in experimental colitis induced by dextran sodium sulfate (DSS) was examined.\nMETHODS: IL-1beta production in response to DSS was studied in macrophages of wild-type, caspase-1(-/-), NLRP3(-/-), ASC(-/-), cathepsin B(-/-) or cathepsin L(-/-) mice. Colitis was induced in C57BL/6 and NLRP3(-/-) mice by oral DSS administration. A clinical disease activity score was evaluated daily. Histological colitis severity and expression of cytokines were determined in colonic tissue.\nRESULTS: Macrophages incubated with DSS in vitro secreted high levels of IL-1beta in a caspase-1-dependent manner. IL-1beta secretion was abrogated in macrophages lacking NLRP3, ASC or caspase-1, indicating that DSS activates caspase-1 via the NLRP3 inflammasome. Moreover, IL-1beta secretion was dependent on phagocytosis, lysosomal maturation, cathepsin B and L, and reactive oxygen species (ROS). After oral administration of DSS, NLRP3(-/-) mice developed a less severe colitis than wild-type mice and produced lower levels of proinflammatory cytokines in colonic tissue. Pharmacological inhibition of caspase-1 with pralnacasan achieved a level of mucosal protection comparable with NLRP3 deficiency.\nCONCLUSIONS: The NLRP3 inflammasome was identified as a critical mechanism of intestinal inflammation in the DSS colitis model. The NLRP3 inflammasome may serve as a potential target for the development of novel therapeutics for patients with IBD.
科研通智能强力驱动
Strongly Powered by AbleSci AI